BioNTech SE (BNTX) Reports Q3 EPS of EUR12.35

BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR12.35, versus (EUR0.88) reported last year. Revenue for the quarter came in at EUR6.09 billion, versus EUR67.5 million reported last year.

Guidance:

Estimated BioNTech COMIRNATY/COVID-19 vaccine revenues for the full 2021 financial year based on up to 2.5 billion doses: ~€16 billion to €17 billion2

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance